Alzamend Neuro (NASDAQ:ALZN) Posts Earnings Results, Misses Expectations By $0.12 EPS

Alzamend Neuro (NASDAQ:ALZN) announced its quarterly earnings results on Thursday. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.12), FiscalAI reports.

Alzamend Neuro Trading Up 1.2%

Alzamend Neuro stock traded up $0.02 during midday trading on Thursday, reaching $1.70. 8,709 shares of the stock traded hands, compared to its average volume of 126,647. Alzamend Neuro has a fifty-two week low of $0.84 and a fifty-two week high of $2.68. The firm has a market cap of $8.21 million, a price-to-earnings ratio of -0.59 and a beta of 0.23. The firm has a fifty day moving average price of $1.42 and a two-hundred day moving average price of $1.37.

Analyst Ratings Changes

Separately, Weiss Ratings raised Alzamend Neuro from a “sell (e)” rating to a “sell (e+)” rating in a research report on Monday, August 31st. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Alzamend Neuro has a consensus rating of “Hold” and a consensus target price of $28.00.

Institutional Investors Weigh In On Alzamend Neuro

A hedge fund recently raised its position in Alzamend Neuro stock. DRW Securities LLC increased its holdings in Alzamend Neuro, Inc. (NASDAQ:ALZN) by 27.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 116,319 shares of the company’s stock after buying an additional 25,074 shares during the quarter. DRW Securities LLC owned about 3.06% of Alzamend Neuro worth $212,000 at the end of the most recent reporting period. 49.61% of the stock is currently owned by institutional investors and hedge funds.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.